Ethosuximide

When ATH:
N03AD01

Pharmacological action.
Anticonvulsant, miorelaksiruyuschee, analgesic.

Application.
Small seizures: piknolepticheskie absences, complex or atypical seizure seizures, myoclonic-astatic small seizures (little evil), juvenile myoclonic seizures (impulsive small seizures).
Contraindications.

Hypersensitivity, liver and / or kidney failure, blood disease, porphyria.

Pregnancy and breast-feeding.

Not recommended for use during pregnancy. At the time of treatment should stop breastfeeding.

Side effects.

From the nervous system and sensory organs: possible-ataxia, dyskinesia, dizziness, drowsiness, headache, irritability, increased fatigue, poor concentration, aggressiveness, depression, strengthening tonic-clonic seizures, hallucinatory-paranoid disorder, parkinsonizm.

From the digestive tract: possible-hiccups, nausea, vomiting, loss of appetite, diarrhea / constipation.

Cardio-vascular system and blood (hematopoiesis, hemostasis): possible-leiko-, trombotsito-, pancytopenia, agranulocytosis, aplasticheskaya anemia, eozinofilija.

Other: possible syndrome Stevens-Johnson, lupus-like syndrome, photophobia, albuminuria, weight loss.

Cooperation.

Carbamazepine accelerates metabolism and lowers plasma. Significantly changes the (decreases or increases) ethosuximide valproic acid in the blood.

Overdose.

Symptoms: fatigue, decreased physical activity, loss of interest in the surroundings, depressed mood, hypererethism, irritability.

Treatment: gastric lavage, administration of activated charcoal; When the need for symptomatic treatment in a hospital.

Dosing and Administration.

Inside, the dose is selected strictly individually, depending on the clinical, individual patient response and tolerability of medicines. Initial daily dose for adults and children is 5-10 mg/kg, with a gradual increase in 5 mg/kg every 4-7 days; frequency reception is 1-3 times a day. The maximum daily dose for adults is 30 mg / kg, children — 40 mg / kg, supporting — 15 mg / kg 20 mg / kg, respectively,.

Precautions.

Should not be used during the drivers of vehicles and people, skills relate to the high concentration of attention. During the period of treatment is necessary to completely eliminate the use of alcohol.

Cooperation

Active substanceDescription of interaction
Valproic AcidFKV. FMR. Inhibits biotransformation, extends T1/2, reduces the total clearance and, usually, increases (mutually) effect.
HaloperidolFMR: antagonizm. Weakens effect (may lower the seizure threshold); with a joint appointment requires increasing the dose.
CarbamazepineFKV. FMR. Accelerates biotransformation (induces the activity of CYP450), lowers plasma, weakens the effect.
ClonazepamFMR: synergism. Strengthens (mutually) CNS depression.
PhenytoinFKV. Against the background of ethosuximide may increase serum levels.

Back to top button